ENO2 and neoplasm: In contrast, there were no statistically significant differences in tumor functionality, levels of serum neuron specific enolase, primary tumor sites, proportion of patients presenting with typical symptoms, or RET/VHL/SDHD/SDHA/MAX mutation frequencies between the two groups (Table 1).